17:42:04 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Diagnos Inc (3)
Symbol ADK
Shares Issued 65,625,925
Close 2021-01-27 C$ 0.57
Market Cap C$ 37,406,777
Recent Sedar Documents

Diagnos reopens health operations in Panama

2021-01-28 12:31 ET - News Release

Mr. Andre Larente reports

DIAGNOS ANNOUNCES THE RE-OPENING OF ITS MEDICAL TESTING IN PANAMA

Diagnos Inc. has reopened its operations in Panama.

"Following a long-standing presence in Panama and in collaboration with Retina & Eye, Diagnos's distributor, we have proven the effectiveness of Diagnos's AI solution. After overcoming the current lockdown of the pandemic, CliniLab is pleased to announce it is resuming operations with different types of projects in the public and private health sectors in Panama, which will add value to our patients in partnership with Diagnos. The implementation experience of Diagnos's technology is remarkable, its turnkey solution keeps the specialists and the patients safe, and we love the principle that AI provides. It's a pure driven technology approach without replacing the most important factor, the human factor, where specialists follow up with patients using the telemedicine digital tool. We're adopting this new technology to positively impact the health market in Panama, and we're doing it with Diagnos," said Katherine Prieto, director of operations from CliniLab Panama.

"This is a great opportunity for Diagnos to demonstrate that our medical technology platform can easily interconnect, not only with the ophthalmologists, but cardiologists as well. Our CARA platform offers a real-time analysis that is beneficial for both areas of specialties which is provided by our telemedicine-AI-based services to screen the general population. Early screening is key and starts at the age of 20 in order to detect and prevent avoidable blindness in real time. We've carefully designed not only our high-tech solution, but we've also put a protocol in place and a rollout plan for CliniLab's flagship telemedicine service in order to make it a sustainable project. This will allow our retina service to remain part of every patient's check-up and refer them accordingly to each specialists," said Andre Larente, president of Diagnos.

About Clinilab

Created in 2019, the main corporate purpose is the development, design, planning and operations of health services, specifically in the management of general and specialized medicine clinic by integrating clinical laboratory services certified by the Technical Health Council as a Level 2 laboratory: hematology, special chemistry, general chemistry and serological test. Focused on being the main reference among the private hospitals in the nation, Clinilab makes available to its clients the following services: general medicine, specialized medicine, telemedicine, Level 2 clinical laboratory, home or business care, collective sampling, medical care through Clinilab's mobile unit, among others.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer assisted retina analysis). CARA's AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (United States), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.